Thrombolytic agents for acute ischaemic stroke treatment: The past, present and future

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 145-154

  Balami, Joyce S ^a   Chen, Ruoli ^b,c   Sutherland, Brad A ^c   Buchan, Alastair M ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

Direct fibrinolytics; Ischaemic stroke; Plasminogen activators; Thrombolysis; Thrombolytics

Indexed keywords

ABCIXIMAB; ALFIMEPRASE; ALTEPLASE; ANCROD; ANTICOAGULANT AGENT; DESMOTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; OCRIPLASMIN; PLACEBO; PLASMIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE; V 10153;

ASPIRATION PNEUMONIA; BLEEDING; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; KIDNEY FAILURE; MECHANICAL THROMBECTOMY; META ANALYSIS (TOPIC); MORTALITY; NEUROPROTECTION; NEUROTOXICITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECANALIZATION; REVIEW;

ANIMALS; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STROKE; THROMBOLYTIC THERAPY;

EID: 84876700616     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990057     Document Type: Review

References (87)

1. Saver, J.L. Time is brain-quantified. Stroke 2006, 37 (1), 263-6.
2. NINDS, Tissue plasminogen activator for acute ischaemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med., 1995, 333(24), 1581-1587.
3. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Davalos, A.; Guidetti, D.; Larrue, V.; Lees, K.R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N. Engl. J. Med., 2008, 359(13), 1317-1329.
4. Del Zoppo, G.J.; Saver, J.L.; Jauch, E.C.; Adams, H.P. Jr. Expansion of the time window for treatment of acute ischaemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke, 2009, 40(8), 2945-2948.
5. ESO ESO Guidelines for Management of Ischaemic Stroke Update 2009. http://www.esostroke.org/pdf/ESO_Guideline_Update_Jan_2009.pdf (accessed 08/06/2012).
6. Kleindorfer, D.; Xu, Y.; Moomaw, C.J.; Khatri, P.; Adeoye, O.; Hornung, R. US geographic distribution of rt-PA utilization by hospital for acute ischaemic stroke. Stroke, 2009, 40 (11), 3580-3584.
7. Leyden, J.M.; Chong, W.K.; Kleinig, T.; Lee, A.; Field, J.B.; Jannes, J. A population-based study of thrombolysis for acute stroke in South Australia. Med. J. Aust., 2011, 194(3), 111-115.
8. RCP Royal College of Physicians of London. National Sentinel Stroke Audit Organisational Audit 2010. Public report for England, Wales and Northern Ireland. http://www.rcplondon.ac.uk/sites/default/files/2010-stroke-publicreport.pdf (accessed 30/07/2012).
9. Wang, D.Z.; Rose, J.A.; Honings, D.S.; Garwacki, D.J.; Milbrandt, J.C. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke, 2000, 31(1), 77-81.
10. Wardlaw, J.M.; Murray, V.; Berge, E.; del Zoppo, G.; Sandercock, P.; Lindley, R.L.; Cohen, G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet, 2012, 379(9834), 2364-2372.
11. Adams, H.P., Jr.; del Zoppo, G.; Alberts, M.J.; Bhatt, D.L.; Brass, L.; Furlan, A.; Grubb, R.L.; Higashida, R.T.; Jauch, E.C.; Kidwell, C.; Lyden, P.D.; Morgenstern, L.B.; Qureshi, A.I.; Rosenwasser, R.H.; Scott, P.A.; Wijdicks, E.F. Guidelines for the early management of adults with ischaemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, 2007, 38(5), 1655-1711.
12. Nogueira, R.G.; Schwamm, L.H.; Hirsch, J.A. Endovascular approaches to acute stroke, part 1: Drugs, devices, and data. AJNR Am. J. Neuroradiol., 2009, 30(4), 649-661.
13. Tillett, W.S.; Garner, R.L. The Fibrinolytic Activity of Hemolytic Streptococci. J. Exp. Med., 1933, 58(4), 485-502.
14. Cornu, C.; Boutitie, F.; Candelise, L.; Boissel, J.P.; Donnan, G.A.; Hommel, M.; Jaillard, A.; Lees, K.R. Streptokinase in acute ischaemic stroke: an individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke, 2000, 31(7), 1555-1560.
15. Regnault, V.; Helft, G.; Wahl, D.; Czitrom, D.; Vuillemenot, A.; Papouin, G.; Roda, L.; Danchin, N.; Lecompte, T. Antistreptokinase platelet-activating antibodies are common and heterogeneous. J. Thromb. Haemost., 2003, 1(5), 1055-1061.
16. Murray, V.; Norrving, B.; Sandercock, P.A.; Terent, A.; Wardlaw, J.M.; Wester, P. The molecular basis of thrombolysis and its clinical application in stroke. J. Intern. Med., 2010, 267(2), 191-208.
17. Mori, E.; Tabuchi, M.; Yoshida, T.; Yamadori, A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke, 1988, 19(7), 802-812.
18. Hacke, W.; Zeumer, H.; Ferbert, A.; Bruckmann, H.; del Zoppo, G.J. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke, 1988, 19(10), 1216-1222.
19. Cooperating Group for National 95s Project. Intravenous thrombolysis with urokinase for acute cerebral infarctions. Chin. J. Neurol., 2002, 35(4), 210-213.
20. Macleod, M.R.; Davis, S.M.; Mitchell, P.J.; Gerraty, R.P.; Fitt, G.; Hankey, G.J.; Stewart-Wynne, E.G.; Rosen, D.; McNeil, J.J.; Bladin, C.F.; Chambers, B.R.; Herkes, G.K.; Young, D.; Donnan, G.A. Results of a multicentre, randomised controlled trial of intraarterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc. Dis., 2005, 20(1), 12-17.
21. Ogawa, A.; Mori, E.; Minematsu, K.; Taki, W.; Takahashi, A.; Nemoto, S.; Miyamoto, S.; Sasaki, M.; Inoue, T. Randomised trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke, 2007, 38(10), 2633-2639.
22. Lees, K.R.; Bluhmki, E.; von Kummer, R.; Brott, T.G.; Toni, D.; Grotta, J.C.; Albers, G.W.; Kaste, M.; Marler, J.R.; Hamilton, S.A.; Tilley, B.C.; Davis, S.M.; Donnan, G.A.; Hacke, W.; Allen, K.; Mau, J.; Meier, D.; del Zoppo, G.; De Silva, D.A.; Butcher, K.S.; Parsons, M.W.; Barber, P.A.; Levi, C.; Bladin, C.; Byrnes, G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375(9727), 1695-1703.
23. Sandercock, P.; Wardlaw, J.M.; Lindley, R.I.; Dennis, M.; Cohen, G.; Murray, G.; Innes, K.; Venables, G.; Czlonkowska, A.; Kobayashi, A.; Ricci, S.; Murray, V.; Berge, E.; Slot, K.B.; Hankey, G.J.; Correia, M.; Peeters, A.; Matz, K.; Lyrer, P.; Gubitz, G.; Phillips, S.J.; Arauz, A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, 2012, 379(9834), 2352-2363.
24. Harston, G.W.; Sutherland, B.A.; Kennedy, J.; Buchan, A.M. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischaemia: a review of rt-PA neurotoxicity. J. Cereb. Blood Flow Metab., 2010, 30(11), 1804-1816.
25. Wang, Y.F.; Tsirka, S.E.; Strickland, S.; Stieg, P.E.; Soriano, S.G.; Lipton, S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischaemia in wild-type and tPAdeficient mice. Nat. Med., 1998, 4(2), 228-231.
26. Sumii, T.; Lo, E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischaemia in rats. Stroke, 2002, 33(3), 831-836.
27. Yepes, M.; Roussel, B.D.; Ali, C.; Vivien, D. Tissue-type plasminogen activator in the ischaemic brain: more than a thrombolytic. Trends Neurosci., 2009, 32(1), 48-55.
28. Nicole, O.; Docagne, F.; Ali, C.; Margaill, I.; Carmeliet, P.; MacKenzie, E.T.; Vivien, D.; Buisson, A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptormediated signaling. Nat. Med., 2001, 7(1), 59-64.
29. Park, L.; Gallo, E.F.; Anrather, J.; Wang, G.; Norris, E.H.; Paul, J.; Strickland, S.; Iadecola, C. Key role of tissue plasminogen activator in neurovascular coupling. Proc. Natl. Acad. Sci. USA, 2008, 105(3), 1073-1078.
30. Kaur, J.; Zhao, Z.; Klein, G.M.; Lo, E.H.; Buchan, A.M. The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood Flow Metab., 2004, 24(9), 945-963.
31. Chavez, J.C.; Hurko, O.; Barone, F.C.; Feuerstein, G.Z. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke, 2009, 40(10), e558-e563.
32. Woodruff, T.M.; Thundyil, J.; Tang, S.C.; Sobey, C.G.; Taylor, S.M.; Arumugam, T.V. Pathophysiology, treatment, and animal and cellular models of human ischaemic stroke. Mol. Neurodegener., 2011, 6(1), 11.
33. Ramos-Cabrer, P.; Campos, F.; Sobrino, T.; Castillo, J. Targeting the ischaemic penumbra. Stroke, 2011, 42(1 Suppl), S7-S11.
34. Balami, J.S.; Sutherland, B.A.; Buchan, A.M. Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol. Disord. Drug Targets, 2013, 12(2), XXX-XXX.
35. Del Zoppo, G.J.; Higashida, R.T.; Furlan, A.J.; Pessin, M.S.; Rowley, H.A.; Gent, M. PROACT: a phase II randomised trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke, 1998, 29(1), 4-11.
36. Furlan, A.; Higashida, R.; Wechsler, L.; Gent, M.; Rowley, H.; Kase, C.; Pessin, M.; Ahuja, A.; Callahan, F.; Clark, W.M.; Silver, F.; Rivera, F. Intra-arterial prourokinase for acute ischaemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA, 1999, 282(21), 2003-2011.
37. Kohnert, U.; Rudolph, R.; Verheijen, J.H.; Weening-Verhoeff, E.J.; Stern, A.; Opitz, U.; Martin, U.; Lill, H.; Prinz, H.; Lechner, M.; et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng., 1992, 5(1), 93-100.
38. Seifried, E.; Muller, M.M.; Martin, U.; Konig, R.; Hombach, V. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system. Ann. NY Acad. Sci., 1992, 667, 417-420.
39. van Zonneveld, A.J.; Veerman, H.; Pannekoek, H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA, 1986, 83(13), 4670-4674.
40. Fischer, S.; Kohnert, U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinol. Proteol., 1997, 11(3), 129-135.
41. Qureshi, A.I.; Ali, Z.; Suri, M.F.; Kim, S.H.; Shatla, A.A.; Ringer, A.J.; Lopes, D.K.; Guterman, L.R.; Hopkins, L.N. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischaemic stroke. Neurosurgery, 2001, 49(1), 41-48;discussion 48-50.
42. Qureshi, A.I.; Siddiqui, A.M.; Suri, M.F.; Kim, S.H.; Ali, Z.; Yahia, A.M.; Lopes, D.K.; Boulos, A.S.; Ringer, A.J.; Saad, M.; Guterman, L.R.; Hopkins, L.N. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischaemic stroke: a prospective study. Neurosurgery, 2002, 51(5), 1319-1327; discussion 1327-1329.
43. Qureshi, A.I.; Harris-Lane, P.; Kirmani, J.F.; Janjua, N.; Divani, A.A.; Mohammad, Y.M.; Suarez, J.I.; Montgomery, M.O. Intraarterial reteplase and intravenous abciximab in patients with acute ischaemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery, 2006, 59(4), 789-796; discussion 796-797.
44. ReoPro and Retavase to Treat Acute Stroke. http://clinicaltrials.gov/ct2/show/NCT00046293?term=00046293&rank=1 (accessed 06/08/2012).
45. Davydov, L.; Cheng, J.W. Tenecteplase: a review. Clin. Ther., 2001, 23(7), 982-997;discussion 981.
46. Van De Werf, F.; Adgey, J.; Ardissino, D.; Armstrong, P.W.; Aylward, P.; Barbash, G.; Betriu, A.; Binbrek, A.S.; Califf, R.; Diaz, R.; Fanebust, R.; Fox, K.; Granger, C.; Heikkila, J.; Husted, S.; Jansky, P.; Langer, A.; Lupi, E.; Maseri, A.; Meyer, J.; Mlczoch, J.; Mocceti, D.; Myburgh, D.; Oto, A.; Paolasso, E.; Pehrsson, K.; Seabra-Gomes, R.; Soares-Piegas, L.; Sugrue, D.; Tendera, M.; Topol, E.; Toutouzas, P.; Vahanian, A.; Verheugt, F.; Wallentin, L.; White, H. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT- 2 double-blind randomised trial. Lancet, 1999, 354(9180), 716-722.
47. Haley, E.C., Jr.; Lyden, P.D.; Johnston, K.C.; Hemmen, T.M. A pilot dose-escalation safety study of tenecteplase in acute ischaemic stroke. Stroke, 2005, 36(3), 607-612.
48. Haley, E.C., Jr.; Thompson, J.L.; Grotta, J.C.; Lyden, P.D.; Hemmen, T.G.; Brown, D.L.; Fanale, C.; Libman, R.; Kwiatkowski, T.G.; Llinas, R.H.; Levine, S.R.; Johnston, K.C.; Buchsbaum, R.; Levy, G.; Levin, B. Phase IIB/III trial of tenecteplase in acute ischaemic stroke: results of a prematurely terminated randomised clinical trial. Stroke, 2010, 41(4), 707-711.
49. Parsons, M.W.; Miteff, F.; Bateman, G.A.; Spratt, N.; Loiselle, A.; Attia, J.; Levi, C.R. Acute ischaemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology, 2009, 72(10), 915-921.
50. Molina, C.A.; Ribo, M.; Rubiera, M.; Santamarina, E.; Delgado- Mederos, R.; Maisterra, O.; Delgado, P.; Dinia, L.; Pontes, O.; Montaner, J.; Alvarez-Sabin, J. TNK induces faster MCA recanalization and leads to better short- and long-term clinical outcomes than native tPA. The TNK-TPA reperfusion stroke study[abstract]. Stroke, 2008, 39, 563.
51. Parsons, M.; Spratt, N.; Bivard, A.; Campbell, B.; Chung, K.; Miteff, F.; O'Brien, B.; Bladin, C.; McElduff, P.; Allen, C.; Bateman, G.; Donnan, G.; Davis, S.; Levi, C. A randomised trial of tenecteplase versus alteplase for acute ischaemic stroke. N. Engl. J. Med., 2012, 366(12), 1099-1107.
52. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST). http://clinicaltrials.gov/ct2/show/NCT01472926?term=01472926&rank=1 (accessed 06/08/2012).
53. Saver, J.L. Improving reperfusion therapy for acute ischaemic stroke. J. Thromb. Haemost., 2011, 9(Suppl 1), 333-343.
54. Ellis, V.; Daniels, M.; Misra, R.; Brown, D.R. Plasminogen activation is stimulated by prion protein and regulated in a copperdependent manner. Biochemistry, 2002, 41(22), 6891-6896.
55. Kingston, I.B.; Castro, M.J.; Anderson, S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid betapeptide analogues. Nat. Med., 1995, 1(2), 138-142.
56. Paciaroni, M.; Medeiros, E.; Bogousslavsky, J. Desmoteplase. Exp. Opin. Biol. Ther., 2009, 9(6), 773-778.
57. Liberatore, G.T.; Samson, A.; Bladin, C.; Schleuning, W.D.; Medcalf, R.L. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke, 2003, 34(2), 537-543.
58. Furlan, A.J.; Eyding, D.; Albers, G.W.; Al-Rawi, Y.; Lees, K.R.; Rowley, H.A.; Sachara, C.; Soehngen, M.; Warach, S.; Hacke, W. Dose Escalation of Desmoteplase for Acute Ischaemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke, 2006, 37(5), 1227-1231.
59. Hacke, W.; Albers, G.; Al-Rawi, Y.; Bogousslavsky, J.; Davalos, A.; Eliasziw, M.; Fischer, M.; Furlan, A.; Kaste, M.; Lees, K.R.; Soehngen, M.; Warach, S. The Desmoteplase in Acute Ischaemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke, 2005, 36 (1), 66-73.
60. Hacke, W.; Furlan, A.J.; Al-Rawi, Y.; Davalos, A.; Fiebach, J.B.; Gruber, F.; Kaste, M.; Lipka, L.J.; Pedraza, S.; Ringleb, P.A.; Rowley, H.A.; Schneider, D.; Schwamm, L.H.; Leal, J.S.; Sohngen, M.; Teal, P.A.; Wilhelm-Ogunbiyi, K.; Wintermark, M.; Warach, S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebocontrolled study. Lancet Neurol., 2009, 8(2), 141-150.
61. Marder, V.J.; Novokhatny, V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J. Thromb. Haemost., 2009, 8(3), 433-444.
62. Marder, V.J.; Stewart, D. Towards safer thrombolytic therapy. Semin. Hematol., 2002, 39(3), 206-216.
63. Marder, V.J.; Landskroner, K.; Novokhatny, V.; Zimmerman, T.P.; Kong, M.; Kanouse, J.J.; Jesmok, G. Plasmin induces local thrombolysis without causing haemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb. Haemost., 2001, 86(3), 739-745.
64. A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion (PRIORITY). http://clinicaltrials.gov/ct2/show/NCT00418483?term=00418483&rank=1 (accessed 06/08/2012).
65. Marder, V.J.; Comerota, A.J.; Shlansky-Goldberg, R.D.; Davis, J.P.; Deng, C.; Hanna, K.; Fineberg, D. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results. J. Thromb. Haemost., 2012, 10(6), 985-991.
66. Marder, V.J.; Jahan, R.; Gruber, T.; Goyal, A.; Arora, V. Thrombolysis with plasmin: implications for stroke treatment. Stroke, 2010, 41(10 Suppl), S45-S49.
67. Marder, V.J. Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. J. Thromb. Haemost., 2011, 9(Suppl 1), 364-373.
68. Molina, C.A.; Saver, J.L. Extending reperfusion therapy for acute ischaemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke, 2005, 36(10), 2311-2320.
69. Lapchak, P.A.; Araujo, D.M.; Pakola, S.; Song, D.; Wei, J.; Zivin, J.A. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke, 2002, 33(9), 2279-2284.
70. Thijs, V.N.; Peeters, A.; Vosko, M.; Aichner, F.; Schellinger, P.D.; Schneider, D.; Neumann-Haefelin, T.; Rother, J.; Davalos, A.; Wahlgren, N.; Verhamme, P. Randomised, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischaemic stroke. Stroke, 2009, 40(12), 3789-3795.
71. Intra-Arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion (MITI-IA). http://clinicaltrials.gov/ct2/show/NCT00123266?term=00123266&rank=1 (accessed 06/08/2012).
72. Deitcher, S.R.; Funk, W.D.; Buchanan, J.; Liu, S.; Levy, M.D.; Toombs, C.F. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Exp. Opin. Biol. Ther., 2006, 6(12), 1361-1369.
73. Deitcher, S.R.; Toombs, C.F. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase. Pathophysiol. Haemost. Thromb., 2005, 34(4-5), 215-220.
74. Alfimeprase. Drugs RD, 2008, 9(3), 185-190.
75. Pawsey, S.; Hutchison, J.H.; Munro, S.; Barsikian, N.A. VASTT - The V10153 acute stroke thrombolysis trial. Int. J. Stroke, 2006, 1(Supplement s2), 45.
76. Atkinson, R.P. Ancrod in the treatment of acute ischaemic stroke. Drugs, 1997, 54(Suppl 3), 100-108.
77. Sherman, D.G.; Atkinson, R.P.; Chippendale, T.; Levin, K.A.; Ng, K.; Futrell, N.; Hsu, C.Y.; Levy, D.E. Intravenous ancrod for treatment of acute ischaemic stroke: the STAT study: a randomised controlled trial. Stroke Treatment with Ancrod Trial. JAMA, 2000, 283(18), 2395-2403.
78. ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischaemic Stroke. http://clinicaltrials.gov/ct2/show/NCT00300196 (accessed 06/08/2012).
79. Rha, J.H.; Saver, J.L. The impact of recanalization on ischaemic stroke outcome: a meta-analysis. Stroke, 2007, 38(3), 967-973.
80. Sanak, D.; Kuliha, M.; Herzig, R.; Roubec, M.; Skoloudik, D.; Zapletalova, J.; Kocher, M.; Kral, M.; Veverka, T.; Cechakova, E.; Bartkova, A.; Prochazka, V.; Kanovsky, P. Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis. Eur. Neurol., 2012, 67(1), 52-56.
81. Grotta, J.C.; Welch, K.M.; Fagan, S.C.; Lu, M.; Frankel, M.R.; Brott, T.; Levine, S.R.; Lyden, P.D. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke, 2001, 32(3), 661-668.
82. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 1988, 2(8607), 349-360.
83. Zinkstok, S.M.; Roos, Y.B. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet, 2012, 380(9843), 731-737.
84. O'Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol., 2006, 59(3), 467-477.
85. Grotta, J. Combination Therapy Stroke Trial: recombinant tissuetype plasminogen activator with/without lubeluzole. Cerebrovasc. Dis., 2001, 12(3), 258-263.
86. Lyden, P.; Jacoby, M.; Schim, J.; Albers, G.; Mazzeo, P.; Ashwood, T.; Nordlund, A.; Odergren, T. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology, 2001, 57(7), 1199-1205.
87. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; Emeribe, U. NXY-059 for the treatment of acute ischaemic stroke. N. Engl. J. Med., 2007, 357(6), 562-571.